← Leaderboards
David W. Mullins
University Of Virginia
$1,874,608
Attributed
$1,874,608
Total exposure
3
Grants
3
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $318K · FY2009–18$500K$375K$250K$125K$0
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
Funding mix
By agency
NIH$1,874,608 · 3
By mechanism
R01$1,550,608 · 1
R03$324,000 · 2
Top collaborators
No co-investigators on record.
Most similar at University Of Virginia
Same institution · by research overlap
- Tajie H. Harris$6,102,758
- David R Brenin$407,704
- Kimberly A Bullock$314,363
- Craig Lee Slingluff$18,119,839
- George Cortina$72,490
Others in their field
Top investigators on “Immune”
- Lawrence Corey · Fred Hutchinson Cancer Center$680,290,567
- Margaret Juliana McElrath · Fred Hutchinson Cancer Center$541,067,641
- Bambra Strokes · Ppd Development Lp$526,656,217
- Barton F Haynes · Duke University$470,748,611
- Glenda E Gray · Wits Health Consortium (Pty), Ltd$342,310,423
- Judith S. Currier · University Of California Los Angeles$334,425,492
Research focus
ImmuneCxcr3 GeneCancer VaccinesCancer ImmunotherapyT-LymphocyteCellsTumorInfiltrationImmunotherapyImmunologicsMediatingChemokine ReceptorMelanomaMolecularBaseNeoplasm MetastasisCd8b1 GeneMemoryMouse ModelAntigensImmunizationAdjuvantHomingTissues
Grant awards (10)
Beta-adrenergic mediated suppression of T cell chemotaxis by cancers$81,000
R03 · FY2018 · CA · contact PI
Beta-adrenergic mediated suppression of T cell chemotaxis by cancers$81,000
R03 · FY2017 · CA · contact PI
Combinational Therapy of Melanoma using T Cells and site-specific Immunomodulators$81,000
R03 · FY2016 · CA · contact PI
Combinational Therapy of Melanoma using T Cells and site-specific Immunomodulators$81,000
R03 · FY2015 · CA · contact PI
Role of CXCR3 for CD8+ T cells in cancer immunotherapy$298,935
R01 · FY2013 · CA · contact PI
Role of CXCR3 for CD8+ T cells in cancer immunotherapy$318,015
R01 · FY2012 · CA · contact PI
Role of CXCR3 for CD8+ T cells in cancer immunotherapy$168,140
R01 · FY2011 · CA · contact PI
Role of CXCR3 for CD8+ T cells in cancer immunotherapy$136,792
R01 · FY2011 · CA · contact PI
Role of CXCR3 for CD8+ T cells in cancer immunotherapy$314,363
R01 · FY2010 · CA · contact PI
Role of CXCR3 for CD8+ T cells in cancer immunotherapy$314,363
R01 · FY2009 · CA · contact PI